Please use this identifier to cite or link to this item: https://doi.org/10.1038/tpj.2010.12
Title: BDNF Val66Met genotype and 6-month remission rates in late-life depression
Authors: Taylor, W.D.
McQuoid, D.R.
Ashley-Koch, A.
MacFall, J.R.
Bridgers, J.
Krishnan, R.R. 
Steffens, D.C.
Keywords: antidepressant response
BDNF
genetic polymorphism
geriatrics
major depressive disorder
Issue Date: Apr-2011
Citation: Taylor, W.D., McQuoid, D.R., Ashley-Koch, A., MacFall, J.R., Bridgers, J., Krishnan, R.R., Steffens, D.C. (2011-04). BDNF Val66Met genotype and 6-month remission rates in late-life depression. Pharmacogenomics Journal 11 (2) : 146-154. ScholarBank@NUS Repository. https://doi.org/10.1038/tpj.2010.12
Abstract: Although not observed in younger adult cohorts, in older individuals the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with major depressive disorder (MDD) risk. It is further associated with subjective social support and magnetic resonance imaging (MRI) hyperintense lesions, clinical features independently related to MDD. We examined the relationship between this polymorphism and antidepressant remission rates in an elderly sample with MDD, while also testing for mediation effects of social support and hyperintensities. A total of 229 elderly Caucasian subjects with MDD completed baseline assessments, 1.5 T MRI, and BDNF genotyping. They received antidepressant medication under a structured treatment algorithm and were evaluated for remission at 3 and 6 months. At the 3-month evaluation, BDNF Val66Met genotype was not associated with remission (Wald's X2 = 2.51, P=0.1131). When not controlling for multiple comparisons, Met66 allele carriers were more likely to be remitted at 6 months ( X2 = 4.32, P=0.0377) with an odds ratio of 1.82 (95% CI: 1.04, 3.22). This effect persisted after controlling for lesion volume and social support, neither of which mediated this relationship. Thus in this exploratory analysis, the Met66 allele may be associated with increased odds of remission in older subjects, but also with increased time to remission as there was no 3-month effect. © 2011 Macmillan Publishers Limited. All rights reserved.
Source Title: Pharmacogenomics Journal
URI: http://scholarbank.nus.edu.sg/handle/10635/110494
ISSN: 1470269X
DOI: 10.1038/tpj.2010.12
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

36
checked on Oct 15, 2018

WEB OF SCIENCETM
Citations

33
checked on Oct 8, 2018

Page view(s)

36
checked on Oct 19, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.